Cargando…
Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a hereditary disease characterized by the presence of renal cysts. Over time the expanding cysts lead to progressive renal failure. The use of tolvaptan, a V(2)-receptor antagonist, was recently approved in ADPKD patients. It was de...
Autores principales: | Pellegrino, Angela Maria, Annicchiarico Petruzzelli, Luigi, Riccio, Eleonora, Pisani, Antonio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6873754/ https://www.ncbi.nlm.nih.gov/pubmed/31752750 http://dx.doi.org/10.1186/s12882-019-1612-7 |
Ejemplares similares
-
Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022) -
The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022) -
Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022) -
Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
por: Agraz-Pamplona, I., et al.
Publicado: (2020) -
Hypertension in autosomal-dominant polycystic kidney disease (ADPKD)
por: Sans-Atxer, Laia, et al.
Publicado: (2013)